Abstracts tagged "Case-based"

Abstract Number: 2319 • 2017 ACR/ARHP Annual Meeting
Bradycardia after High-Dose Solu-Medrol
Deirdre De Ranieri¹ and Umesh Dyamenahalli², ¹Pediatric Rheumatology, The University of Chicago Medicine, Chicago, IL, ²Pediatric Cardiology, University of Chicago, Chicago, IL
Background/Purpose: Methylprednisolone (MP) in both high dose (2mg/kg or higher) and pulse dose (30mg/kg up to 1000mg) is often used to treat patients with connective…
Abstract Number: 116 • 2017 Pediatric Rheumatology Symposium
Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study
Kathryn Phillippi¹, Thomas Sferra², Nora Singer³ and Elizabeth Brooks⁴, ¹Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, ²Pediatric Gastroenterology, Rainbow Babies and Children's Hospital/Case Medical Center, Cleveland, OH, ³MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio, Cleveland, OH, ⁴Division of Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, Cleveland, OH
Background/Purpose: Inflammatory bowel disease (IBD) is associated with extra-intestinal manifestations, the most common of which is arthralgia/arthritis. 4.1- 15% of patients with inflammatory bowel disease…
Abstract Number: 1137 • 2016 ACR/ARHP Annual Meeting
Enhancing Pediatric Rheumatology Education through Computer-Assisted Fellow-Taught Case Modules
Rosemary Peterson¹, Rebecca Blankenburg¹, Michal Cidon² and Joyce Hsu³, ¹Pediatrics, Stanford University, Palo Alto, CA, ²Stanford University, Palo Alto, CA, ³Pediatric Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Teaching is an ACGME milestone for pediatric subspecialty fellows. Despite this expectation, there is little literature regarding how to empower fellows to teach residents.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].